: Qiagen stock rises on announced COVID-19 test

/ / News

Qiagen NV QGEN shares rose in the extended session Wednesday after the Netherlands-based medical diagnostics company said it will begin selling a portable COVID-19 test in the United States. Qiagen shares rose 4% after hours, following a 0.9% rise in the regular session to close at $46.51. Called the “QIAreach SARS-CoV-2 Antigen Test,” the company said the test can process up to 30 swab samples to detect antigens of SARS-CoV-2, the virus that causes COVID-19, in people who are actively infected with the virus in up to 15 minutes. The test was developed by Qiagen in partnership with Australian digital diagnostics company Ellume. Qiagen said the QIAreach “will be particularly valuable when vaccines are introduced.”
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.